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A PCR assay of 43 acute-phase serum samples was evaluated as a method for early detection of human
granulocytic ehrlichiosis (HGE) and determination of etiology when serologic testing is inconclusive. Sequence-
confirmed products of the HGE agent were amplified from three individuals residing or having exposure
history in Minnesota or Wisconsin, and similarly confirmed products from Ehrlichia chaffeensis were amplified
from three individuals from Florida or Maryland. Etiology, as determined by PCR and serology, was the same
whenever there was a fourfold difference between the maximum titers of antibodies to both antigens, indicating
that presumptive determination of etiology may be based on fourfold differences in titers. PCR testing
determined that E. chaffeensis was the etiologic agent for one individual who had similar titers of antibodies to
both agents. PCR assay of acute-phase serum in the absence of whole blood specimens may be a useful method
for early detection of human ehrlichiosis and determination of etiology when serologic testing is inconclusive.
In the United States, human ehrlichiosis results from infec-
tion with either the human granulocytic ehrlichiosis (HGE)
agent (3, 6) or Ehrlichia chaffeensis (9, 10). The Council of
State and Territorial Epidemiologists established a surveil-
lance case definition for ehrlichiosis which requires the pres-
ence of illness clinically compatible with human ehrlichiosis
and relies on indirect immunofluorescence assays (IFA) and
PCR assays for confirmation (5). Laboratory confirmation re-
quires a fourfold change in IFA titer (seroconversion) of an-
tibody to Ehrlichia sp. antigen, amplification of specific ehrli-
chial DNA sequences by PCR assay, or demonstration of
intracytoplasmic microcolonies (morulae) together with a re-
ciprocal titer of $64 (5). Seroconversion has been used to
identify most cases of ehrlichiosis, but it may take 1 month or
longer to obtain an adequate rise in titer (5), and it is often
difficult to obtain convalescent-phase serum samples. Detec-
tion of morulae is not a sensitive technique, especially for E.
chaffeensis (7). PCR assays offer an additional opportunity for
early confirmation of ehrlichiosis.
PCR assays based on the 16S rRNA gene have been used to
detect HGE agent and E. chaffeensis DNAs in acute-phase
EDTA-anticoagulated whole blood (2, 6, 12, 15). Serum can
also serve as a substrate for PCR testing. HGE agent DNA has
been successfully amplified from acute-phase serum from
HGE patients by using two rounds of amplification with the
same primer set (8) or amplification with nested primer sets
(12). In this study, we evaluated a 16S rRNA gene-targeted
nested PCR assay of acute-phase serum as an alternative
method for laboratory diagnosis of human ehrlichiosis.
MATERIALS AND METHODS
Samples. Serum samples, along with patient histories, were submitted to the
Centers for Disease Control and Prevention (CDC) from 1987 to 1997 for
serologic testing by IFA for suspected ehrlichial or rickettsial illness. Samples
were collected from patients with probable or confirmed HGE, i.e., individuals
who had clinically compatible illness and who had at least one titer of $64 of
antibody to the HGE agent (5). We tested three groups of serum samples by
PCR assay: (i) samples collected during the acute phase of illness from patients
who subsequently seroconverted to either the HGE agent or to the HGE agent
and to E. chaffeensis (n 5 20); (ii) samples from suspected HGE cases, when only
one sample had been tested by IFA or when seroconversion did not occur in
paired serum samples (n 5 9); and (iii) samples that were collected from indi-
viduals who were seropositive for both antigens but for whom there was a
less-than-fourfold difference between the maximum titers of antibodies to one
antigen and the other (n 5 14).
We included three samples in which we surmised that ehrlichial microcolonies
(morulae) had been seen in stained peripheral blood smears by the submitting
physicians. Morulae were positively identified in one case, suspected in another,
and referred to as neutrophilic inclusion bodies in the third. Samples originated
from 14 states, including Arkansas (n 5 1), California (n 5 3), Connecticut (n 5
4), Florida (n 5 4), Georgia (n 5 1), Maryland (n 5 2), Minnesota (n 5 2),
Missouri (n 5 3), Montana (n 5 1), New York (n 5 11), North Carolina (n 5
3), Oklahoma (n 5 1), Washington (n 5 1), and Wisconsin (n 5 6). The first
sample submitted to CDC from each suspected case was tested. When an initial
sample was positive, all subsequent serum samples from that patient were tested.
Archived, frozen (270°C), EDTA-anticoagulated whole blood samples from any
of the individuals were tested when available.
IFA. Titers of antibody to the HGE agent were determined by a previously
described IFA that used the USG3 isolate of the HGE agent cultivated in HL-60
cells (13). Titers of antibody to E. chaffeensis had been determined prior to HGE
testing as described previously (10) and were obtained by examination of CDC
records. Samples submitted to CDC prior to 1991 had been tested by using E.
canis as a surrogate antigen for E. chaffeensis, and results for these samples were
combined with those for E. chaffeensis.
Extraction of DNA. Serum was measured (volume in microliters), transferred
into a 1.5-ml conical microtube, and centrifuged at 10,000 3 g for 20 min at 4°C
to pellet any particulate matter. We determined that this method was sufficient
to concentrate cell-free Ehrlichia. Supernatant serum was then removed and
retained for serologic analysis. DNA was extracted from the pellet and the
remaining serum (approximately 20 ml) by using a QIAamp tissue kit (QIAGEN,
Chatsworth, Calif.). Manufacturer recommendations, modified as follows, were
followed. Briefly, 180 ml of lysis buffer (buffer ATL) and 20 ml of proteinase K (10
mg/ml) were added to the remaining pellet suspension. The suspension was
vortexed and incubated at 55°C for 3 h; 200 ml of buffer AL was added, and the
mixture was incubated at 70°C for 10 min. Absolute ethanol (210 ml) was added,
and the entire mixture was placed into a QIAamp column and centrifuged at
6,000 3 g for 1 min. The column was washed twice with 500 ml of buffer AW by
centrifugation (6,000 3 g for 1 min), followed by an additional centrifugation at
10,000 3 g for 2 min to completely remove the wash buffer. DNA was eluted
from the column with 200 ml of buffer AE preheated to 70°C. The loaded column
was incubated at 70°C for 5 min and at room temperature for 1 min before
centrifugation at 6,000 3 g for 1 min. To increase the DNA yield, the 200 ml of
* Corresponding author. Mailing address: Viral and Rickettsial
Zoonoses Branch, National Center for Infectious Diseases, Centers for
Disease Control and Prevention, 1600 Clifton Rd., Mailstop G-13,
Atlanta, GA 30333. Phone: (404) 639-1075. Fax: (404) 639-4436. E-
mail: jnc0@cdc.gov.
31
eluted DNA solution was transferred back to the same column, and the elution
step was repeated. Whole blood (200 ml) was extracted similarly. Final DNA
extracts were stored at 4°C until tested.
PCR assays. PCR assays were prepared by using commercial amplification
reagent kits (GeneAmp; Roche Molecular Systems, Branchburg, N.J.). Five
microliters of template DNA was added to 45 ml of a master mixture in 0.5-ml
reaction tubes prepared as previously described (14). A nested reaction was
conducted on all samples for a total of 80 cycles by using eubacterial 16S rRNA
primers EC9 and EC12 (2) in the first round, followed by primers GE9f and
GE10r for the HGE agent (6). A second PCR substituted primers HE1 and HE3
for E. chaffeensis (1) in the second round. In the first round, the reaction mixture
cycled for 3 preliminary cycles (94°C, 1 min; 48°C, 2 min; 68°C, 1.5 min), followed
by 37 amplification cycles (88°C, 1 min; 55°C, 2 min; 6°C, 1.5 min). An additional
extension period of 5 min at 68°C was added to the final cycle. During the second
round of amplification, the annealing temperature of the reaction was raised to
55°C and the extension temperature was raised to 72°C. A negative control
(gamma-irradiated water), an HGE-positive control (USG3 isolate grown in
HL-60 cells), and an E. chaffeensis-positive control (Arkansas strain grown in
DH-82 cells) were included in every test. PCR products were separated by
agarose gel electrophoresis, stained with ethidium bromide, visualized by UV
illumination, and photographed.
PCR products of the expected sizes (919 bp for the HGE agent, 389 bp for E.
chaffeensis) were sequenced by using an ABI Prism 377 sequencer (ABI, Foster
City, Calif.). Products from E. chaffeensis were further evaluated by amplification
and sequencing of a repetitive-motif sequence (variable-length PCR target
[VLPT]) that has been shown to vary in repeat numbers in different isolates of
E. chaffeensis (15). The PCR primers and parameters used for amplification of
the VLPT have been described previously (15).
Strict precautions were taken to minimize the risk of amplicon contamination
and generation of false-positive results. All positive results were confirmed by
reamplification from the original extract.
RESULTS
Fifty serum samples from 43 patients were tested by using a
nested PCR assay. Products from either the HGE agent or E.
chaffeensis were amplified from serum of six (14%) individuals
residing in Florida, Maryland, Minnesota, and Wisconsin (Ta-
ble 1). One of the patients who was PCR positive for HGE
resided in Florida but had traveled to rural northern Minne-
sota 3 weeks prior to the onset of symptoms, where he was
diagnosed. No ehrlichial DNA was detected in serum from the
remaining 37 patients, including 12 confirmed and 9 probable
cases of HGE, 3 confirmed cases of E. chaffeensis, and 13
individuals who had less-than-fourfold differences between
maximum titers of antibodies to the agents and for whom
etiology was not ascribed.
Of the three individuals who were positive for the HGE agent
by PCR, one was simultaneously seronegative and two were si-
multaneously seropositive for HGE (Table 1). Suspected morulae
were observed in blood smears of the latter two individuals. Sam-
ples that were seronegative or seropositive for E. chaffeensis were
also simultaneously positive by PCR for E. chaffeensis in three
individuals (Table 1). Two of the latter individuals also serocon-
verted to the HGE agent, but the titers of antibodies to E.
chaffeensis were at least fourfold greater. One individual (no. 4)
who was positive for E. chaffeensis by PCR had detectable anti-
bodies to the HGE agent but not to E. chaffeensis in the acute-
phase sample; subsequent samples demonstrated a rise in the
titers of antibodies to both agents (Table 1). No ehrlichial DNA
was detected in second (n 5 6) or third (n 5 1) serum samples
which were collected from the six PCR-positive individuals.
Seven blood samples were available from 6 of the 43 indi-
viduals. E. chaffeensis DNA was amplified from the first of two
blood samples from an individual (no. 4) whose serum was
positive by PCR. No ehrlichial DNA was detected in the re-
maining six blood specimens.
PCR-positive serum samples were collected on days 8, 9, 14,
and 21 following onset of illness (Table 1). Samples collected
from the same individuals on days 25, 27, 30, and 31, respec-
tively, after illness onset were negative by PCR. Dates of serum
collection for 14 PCR-negative individuals ranged from 3 to 32
days (median, 5.5 days) following the onset of symptoms.
Nine individuals received doxycycline therapy during the
course of their illness. Only one PCR-positive patient (no. 3)
received doxycycline therapy, which was given the day after the
serum sample was drawn. Three PCR-negative patients had
received doxycycline therapy from 1 to 3 days before the col-
lection of serum.
TABLE 1. Geographic locations, times from onset of illness to sample collection, titers, and PCR results for
individuals from whose serum ehrlichial DNA was amplified
No. State Sample no. Days POa
Titerb PCR
result
Sequencing
resultE. chaffeensis HGE
1 Wis. 1 8 ,64 ,64 Positive HGE agent
2 25 ,64 512 Negative
2 Minn.c 1 21 ,64 512 Positive HGE agentd
2 31 ,64 4,096 Negative
3 Minn. 1 14 ,64 65,536 Positive HGE agentd
2 30 ,64 1,024 Negative
4 Md. 1 Unavailable ,64 256 Positive E. chaffeensise
2 Unavailable 1 9 256 512 Negative
3 Unavailable 1 26 512 512 Negative
5 Fla. 1 9 1,024 ,64 Positive E. chaffeensis
2 27 4,096 128 Negative
6 Md. 1 Unavailable 256 64 Positive E. chaffeensis
2 Unavailable 1 4 4,096 1,024 Negative
a Days postonset (PO) of symptoms until collection of serum sample.
b E. chaffeensis was tested by using a polyvalent conjugate specific for immunoglobulin G (heavy and light chains); HGE was tested by using a monovalent conjugate
specific for immunoglobulin G (heavy chain) (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.).
c This individual resided in Florida but was exposed and presented in Minnesota.
d Suspected intracytoplasmic inclusion bodies (morulae) were noted on a stained blood smear.
e Acute-phase EDTA-anticoagulated whole blood was also positive by PCR for E. chaffeensis; blood collected 9 days later was negative by PCR.
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The six PCR-positive samples were concentrated from se-
rum volumes of 630 to 1,400 ml (mean, 988 ml). The 37 PCR-
negative samples had volumes of 40 to 1,700 ml (mean, 655 ml),
but the difference was not significant (P . 0.05, Wilcoxon W).
All PCR products were confirmed by nucleotide sequencing
of 16S rRNA gene fragments as belonging to the HGE agent
or E. chaffeensis. All samples that were positive for the E.
chaffeensis 16S rRNA gene by PCR were confirmed by using
VLPT primers. Products from two individuals contained four
repeats, and a similar product was amplified from the blood of
one of these individuals (Table 1). The third patient’s VLPT
product contained five repeats (15).
Etiology, as indicated by the highest serologic antibody titer,
was the same as that indicated by PCR whenever there was a
fourfold difference between the maximum titers of antibodies
to the HGE agent and E. chaffeensis in patients with antibodies
to both antigens (Table 2). By using this criterion, etiology was
ascribed for nine of the individuals tested in this study. Overall,
there were 24 confirmed or probable cases of HGE from nine
states: California (n 5 1), Connecticut (n 5 2), Florida (n 5 3),
Georgia (n 5 1), Minnesota (n 5 2), Montana (n 5 1), New
York (n 5 9), Washington (n 5 1), and Wisconsin (n 5 4).
There were no significant travel histories for HGE cases from
Florida, Georgia, or Montana. There were five cases of E.
chaffeensis from Florida (n 5 1), Maryland (n 5 1), Missouri
(n 5 2), and North Carolina (n 5 1). Etiology was not deter-
mined for 14 individuals from nine states.
DISCUSSION
During the early stages of human ehrlichiosis, serum may
possibly include residual Ehrlichia-infected leukocytes, free
ehrlichiae, or free ehrlichial DNA, all of which may result in a
positive PCR assay. Although a specific and rapid laboratory
diagnosis may occasionally be obtained by PCR testing of
acute-phase serum, this method lacked satisfactory sensitivity
in the present study, as only 6 (14%) of the 43 individuals
tested were positive by PCR.
Because all of the individuals in our study were ill and had
at least one sample that was seropositive for HGE, each rep-
resented at least a probable case of HGE by the Council of
State and Territorial Epidemiologists definition (5). However,
22 (51%) of the 43 individuals were seropositive for E. chaf-
feensis, including five confirmed cases of E. chaffeensis (Table
2). This study and others (13, 16) suggest that a fourfold or
greater difference in maximum titers may be used to infer the
identity of the infecting ehrlichial agent for individuals who are
seropositive for both antigens. Although the HGE agent and
E. chaffeensis IFA used different conjugates, PCR results were
in agreement when serologic results indicated a fourfold or
greater difference in the maximum titers of antibodies to either
agent.
Although only a limited number of samples were evaluated,
the geographic distribution of PCR-positive individuals was
consistent with the known geographic distributions of the two
agents (3, 4, 10, 15, 17). Etiology was confirmed by PCR for
one individual from Maryland whose serologic results were
equivocal (Table 1). Had this individual’s first sample only
been tested by serology, a diagnosis of HGE would have been
suggested. Although simultaneous or prior infection with the
HGE agent cannot be ruled out, the initial response to the
HGE agent underscores the need to use both antigens when
testing for human ehrlichiosis in the United States.
Suspected morulae were detected in blood smears of two of
the patients who were positive for the HGE agent by PCR and
were also noted in a smear from an individual who was nega-
tive by PCR but who strongly seroconverted (titers, ,64 to
4,096) to the HGE agent. The acute-phase sample from the
latter patient had been collected 5 days after antibiotic therapy
had been given. While this may be the cause of the negative
results for this sample, as well as for the three PCR-negative
samples from individuals who had received doxycycline treat-
ment prior to the collection of serum, only 150 ml of this
patient’s serum was available for testing. The sensitivity of
PCR assays has been previously demonstrated to be influenced
by the volume of the clinical sample processed (11); however,
although the mean volume of the positive samples was greater
than the mean volume of the negative samples, the difference
was not significant.
Ehrlichial DNA was detectable in the serum of patients from
days 8 to 21 following the onset of illness, similar to findings
reported by Dumler and Bakken (8), who recovered DNA of
the HGE agent from patient serum from days 2 to 30 after the
onset of illness. They recovered DNA of the HGE agent from
serum that had titers of antibody to E. equi of 160 and 320 and
from seronegative serum samples of two patients. We ampli-
fied the DNAs of both agents from seronegative and seropos-
itive samples, although not simultaneously. To our knowledge,
this is the first report of amplification of E. chaffeensis DNA
from serum.
TABLE 2. Serologic categorization of 43 individuals whose serum samples were selected for testing by PCR
Serum sampling and inferred agent Serologic evidence of infection No. of samplestested
No. (%)
positive
Multiple
HGE agent Seroconversiona to HGE agent; antibodies to HGE agent only present 12 3 (25)
Seroconversion to HGE agent; maximum titer at least fourfold greater
than that of E. chaffeensis
3
Antibodies to HGE agent only; titer of antibody to HGE agent $64
in both samples but no seroconversion
3
E. chaffeensis Seroconversion to E. chaffeensis; maximum titer at least fourfold
greater than that of antibody to HGE agent
5 2 (40)
Undetermined Maximum titer of antibody to one agent less than fourfold greater
than maximum titer of antibody to other agent
9
Single
HGE agent Antibodies to HGE agent only present 6
Undetermined Less-than-fourfold difference in titers 5
a Defined as a fourfold or greater change in titers of immunoglobulin G (gamma chain) for HGE and immunoglobulin G (heavy and light chains) for E. chaffeensis
in successive samples with at least one titer of $64.
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Our data suggest that PCR testing of acute-phase serum is
not a highly sensitive method for the early diagnosis of human
ehrlichiosis. The observed concordance of the PCR and sero-
logic results supports the use of a fourfold difference between
the maximum titers of antibodies to the antigens to infer eti-
ology for patients who react to both antigens. Although the
sensitivity is low, PCR of acute-phase serum in the absence of
whole blood may be used to confirm a diagnosis or determine
etiology when serologic testing is inconclusive.
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